Articles

P45 Donor cell derived deletion 7q occurring after allogeneic stem cell transplantation: a case report

BJH - 2018, issue Abstract Book BHS, february 2018

A. Delie , P. Vlummens MD, N. Van Roy PhD, F. Offner MD, PhD, T. Kerre MD, PhD

Read more

Highlights in multiple myeloma

BJH - volume 8, issue 4, august 2017

P. Vlummens MD

SUMMARY

Now that the anti-CD38 monoclonal antibodies have shown their potency and usefulness, it seems that EHA 2017 gave us the opportunity to direct our gaze towards the other novel players emerging in the therapeutic field of multiple myeloma (MM). As such, the aim of this article is to focus on some of the earlier phase trials, revealing interesting results concerning potentially potent therapeutic and supportive strategies.

(BELG J HEMATOL 2017;8(4):133–6)

Read more

Update on therapy of relapsed and refractory multiple myeloma

BJH - volume 8, issue 2, march 2017

M-C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, K. Fostier MD, A. Kentos MD, P. Mineur MD, M. Vaes MD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, PhD, P. Vlummens MD, K.L. Wu MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD, C. Doyen MD, PhD, On behalf of the Multiple Myeloma Study Group of the Belgian Haematology Society (BHS)

SUMMARY

The prognosis for multiple myeloma patients has improved substantially over the past decade with the development of more effective chemotherapeutic agents and regimens that possess a high level of anti-tumour activity. However, nearly all multiple myeloma patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed disease remains a critical aspect of multiple myeloma care and an important area of ongoing research. This manuscript from the Belgian Haematology Society multiple myeloma subgroup provides some recommendations on the management of relapsed disease.

(BELG J HEMATOL 2017;8(2):53–65)

Read more

P14 The impact of the updated IMWG diagnostic criteria in a real-life SMM cohort: a single center experience

BJH - volume 8, issue Abstract Book BHS, february 2017

P. Vlummens MD, F. Offner MD, PhD

Read more

P17 Diagnostic strength of bone marrow aspirate versus biopsy in (smoldering) multiple myeloma patients

BJH - volume 8, issue Abstract Book BHS, february 2017

P. Vlummens MD, F. Offner MD, PhD

Read more

P40 Successful initial treatment of a cytopenic AML patient with pulmonary leukemic infiltration at diagnosis

BJH - volume 8, issue Abstract Book BHS, february 2017

I. Moors MD, P. Vlummens MD, C. Lecluyse , J. Vermassen

Read more